ClinicalTrials.gg
TerminatedNCT02005484Updated Aug 11, 2014Results posted

A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression

A Phase 2 interventional study of Trastuzumab in Gastric Cancer, sponsored by Hoffmann-La Roche. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated due to slow patient recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing trastuzumab in Stomach Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Trastuzumab · Stomach Neoplasms.

Enrollment
34th of 39
6 · median 40
Started
2004
the only one that year
Phase 2
25 of 40
5 open now
Registered
16th of 40
by date
Lead sponsor
6 of 40
Hoffmann-La Roche

Among the 40 studies testing trastuzumab in Stomach Neoplasms, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2004, is one of 25 in phase 2, and was the 16th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 40 studies testing trastuzumab in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing trastuzumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy. The anticipated time on study treatment is until disease progression.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients 18-75 years of age;
  • or advanced gastric cancer;
  • disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease;
  • >=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;
  • >=1 ;
  • overexpression (IHC [2+] or [3+]).

Exclusion criteria

Exclusion Criteria:

  • concurrent chemotherapy or immunotherapy;
  • brain or meningeal ;
  • cardiac disease, advanced pulmonary disease or severe dyspnoea;
  • co-existing or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ;
  • women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Trastuzumab Monotherapy

    Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit

    Drug: Trastuzumab

Interventions

  • 4 mg/kg initial dose, followed by 2 mg/kg

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category

    Tumor response assessed according to RECIST. Complete response (CR): complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeters \[mm\]); no new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable disease (SD): not qualifying for CR, PR, or progressive disease (PD). Participants who could not be classified per RECIST were allocated as follows: early death from malignant disease (death due to cancer), early death because of other cause (death not related to toxicity or cancer disease), and unknown (for not fitting into the above categories).

    Time frame: Weekly throughout study

Secondary outcomes

  1. Percentage of Participants With Clinical Benefit

    Participants were classified as having a clinical benefit if they had a best overall tumor response of CR, PR, or SD. Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable SD: not qualifying for CR, PR, or PD.

    Time frame: Weekly throughout the study

  2. Percentage of Participants With a Best Overall Response of CR or PR

    Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions.

    Time frame: Weekly throughout the study

  3. Overall Survival - Number of Participants Who Died

    OS was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

    Time frame: Weekly throughout the study

  4. Overall Survival

    Overall survival (OS) was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

    Time frame: Weekly throughout the study

  5. Time to Progression - Number of Participants With an Event

    Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

    Time frame: Weekly throughout the study

  6. Time to Progression

    Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

    Time frame: Weekly throughout the study

07

Results

Posted Aug 11, 2014
Limitations and caveats
Due to slow patient recruitment, the study was prematurely terminated.

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Monotherapy
Started6
Completed2
Not completed4
Withdrew: Death1
Withdrew: Disease progression1
Withdrew: Changed to a different study1
Withdrew: Sponsor decision1

Outcome measures

PrimaryPercentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category

Tumor response assessed according to RECIST. Complete response (CR): complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeters \[mm\]); no new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable disease (SD): not qualifying for CR, PR, or progressive disease (PD). Participants who could not be classified per RECIST were allocated as follows: early death from malignant disease (death due to cancer), early death because of other cause (death not related to toxicity or cancer disease), and unknown (for not fitting into the above categories).

Time frame:
Weekly throughout study
Reported as:
Number · percentage of participants
Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category
percentage of participantsTrastuzumab Monotherapy
CR0
PR33.3
SD0
PD50.0
Early death from malignant disease0
Early death because of other cause16.7
Unknown0
SecondaryPercentage of Participants With Clinical Benefit

Participants were classified as having a clinical benefit if they had a best overall tumor response of CR, PR, or SD. Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. Stable SD: not qualifying for CR, PR, or PD.

Time frame:
Weekly throughout the study
Reported as:
Number · percentage participants
Percentage of Participants With Clinical Benefit
percentage participantsTrastuzumab Monotherapy
Percentage of Participants With Clinical Benefit33.3
SecondaryPercentage of Participants With a Best Overall Response of CR or PR

Tumor response assessed according to RECIST. CR: complete disappearance of all target and non-target lesions, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: ≥30% decrease under baseline of sum of diameters of all target lesions. Short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions.

Time frame:
Weekly throughout the study
Reported as:
Number · percentage participants
Percentage of Participants With a Best Overall Response of CR or PR
percentage participantsTrastuzumab Monotherapy
Percentage of Participants With a Best Overall Response of CR or PR33.3
SecondaryOverall Survival - Number of Participants Who Died

OS was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

Time frame:
Weekly throughout the study
Reported as:
Number · participants
Overall Survival - Number of Participants Who Died
participantsTrastuzumab Monotherapy
Overall Survival - Number of Participants Who Died2
SecondaryOverall Survival

Overall survival (OS) was defined as the time, in months, from the date of study entry to the date of the death due to any cause. If a participant's date of death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

Time frame:
Weekly throughout the study
Reported as:
Median · months
Overall Survival
monthsTrastuzumab Monotherapy
Overall Survival6.39 (1.4 to 18.7)
SecondaryTime to Progression - Number of Participants With an Event

Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

Time frame:
Weekly throughout the study
Reported as:
Number · participants
Time to Progression - Number of Participants With an Event
participantsTrastuzumab Monotherapy
Time to Progression - Number of Participants With an Event5
SecondaryTime to Progression

Time to progression was defined as the time, in months, from the date of study entry to the date of disease progression or death due to any cause. If a participant's date of disease progression or death was unknown, or had not occurred, the last date of examination, treatment, and follow-up dates were included in the analysis.

Time frame:
Weekly throughout the study
Reported as:
Median · months
Time to Progression
monthsTrastuzumab Monotherapy
Time to Progression1.78 (1.4 to 7.4)

Adverse events

Collected over Weekly throughout the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Monotherapy—3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab Monotherapy
Gastrointestinal haemorrhageGastrointestinal disorders1/6
General physical health deteriorationGeneral disorders1/6
HyperkalaemiaMetabolism and nutrition disorders1/6
Renal failureRenal and urinary disorders1/6
Stent placementSurgical and medical procedures1/6
Oesophageal stent insertionSurgical and medical procedures1/6
Oesophageal haemorrhageGastrointestinal disorders1/6
HypersensitivityImmune system disorders1/6
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTrastuzumab Monotherapy
Abdominal painGastrointestinal disorders3/6
NauseaGastrointestinal disorders3/6
DiarrhoeaGastrointestinal disorders2/6
ChillsGeneral disorders2/6
PyrexiaGeneral disorders2/6
AscitesGastrointestinal disorders1/6
ConstipationGastrointestinal disorders1/6
DysphagiaGastrointestinal disorders1/6
FlatulenceGastrointestinal disorders1/6
RetchingGastrointestinal disorders1/6

Baseline characteristics

Intent-to-treat (ITT) population: all participants who signed informed consent for the study.

Age, Continuous
Age, Continuous(years)Trastuzumab Monotherapy
Mean62.49 ± 9.79
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Monotherapy
Female1
Male5
08

Study locations

12 sites
  • Wien, 1090, Austria
  • Dresden, 01307, Germany
  • Erlangen, 91054, Germany
  • Essen, 45122, Germany
  • Grenzach-wyhlen, 79639, Germany
  • Halle, 06120, Germany
  • Kassel, 34125, Germany
  • Kiel, 24105, Germany
  • Mannheim, 68167, Germany
  • München, 81377, Germany
  • München, 81675, Germany
  • Oldenburg, 26133, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 9, 2013
Start
Jan 2004
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Aug 11, 2014
Last update
Aug 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02005484
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Jan 2004
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Aug 11, 2014
Last update
Aug 11, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion